On Thursday, JPMorgan reaffirmed its confidence in ResMed (NYSE:RMD), maintaining an Overweight rating with a steady price target of $240.00. The firm's outlook suggests that while sales growth for ResMed may decelerate compared to the fiscal year 2024, the company is still expected to achieve high single-digit growth rates. This projection comes despite potential market concerns about the impact of new obesity medications and wearable technologies on patient numbers for ResMed's products.
The analyst noted that there are no significant bottlenecks in the diagnosis channel that could hinder ResMed's performance. Additionally, the forecast anticipates that gross margins will continue to improve, bolstered by favorable pricing and product mix. The firm's revenue forecast is approximately 1% higher than the Bloomberg consensus, indicating a slightly more optimistic view of ResMed's sales prospects.
Moreover, JPMorgan's Adjusted Earnings Per Share (EPS) estimate for ResMed stands around 6% above the market consensus. This higher EPS expectation is attributed to an anticipated increase in gross margin and the inclusion of one-off mark-to-market items that are expected to benefit the company's financials.
JPMorgan's analysis suggests that ResMed's financial health remains strong and that the company is well-positioned to continue its growth trajectory. The firm's maintained Overweight rating and price target reflect a positive outlook on ResMed's stock performance in the market.
In other recent news, ResMed has been the focus of several analyst firms following the presentation of its 2030 Plan, which includes strategic initiatives aimed at driving growth. Mizuho and Baird both maintained an Outperform rating on ResMed, citing confidence in the company's long-term growth prospects. On the other hand, Wolfe Research downgraded ResMed to Underperform, pointing to potential market disruption.
ResMed reported a 9% increase in group revenue for the fourth quarter of fiscal year 2024, reaching $1.22 billion, primarily driven by strong mask sales in the United States. The company also managed to reduce its debt by $300 million and repurchased 232,000 shares for $50 million.
In terms of future plans, ResMed's management expressed confidence in achieving sustained high-single digit revenue growth, backed by demand generation strategies and market share gains. The company plans to grow its portfolio through strategic acquisitions, focusing on technology-driven and residential care software solutions.
InvestingPro Insights
ResMed's financial metrics and market performance align well with JPMorgan's optimistic outlook. According to InvestingPro data, ResMed's revenue growth stands at 10.95% for the last twelve months as of Q4 2024, supporting JPMorgan's projection of high single-digit growth rates. The company's strong financial health is further evidenced by its robust EBITDA growth of 18.69% over the same period.
InvestingPro Tips highlight that ResMed has maintained dividend payments for 13 consecutive years and has raised its dividend for 12 consecutive years. This consistent dividend policy underscores the company's financial stability and commitment to shareholder returns, which aligns with JPMorgan's positive stance on the stock.
The company's P/E ratio of 34.02 and PEG ratio of 2.5 suggest that while ResMed is trading at a premium, investors are willing to pay for its growth prospects. This valuation is consistent with JPMorgan's Overweight rating and price target of $240, which is close to the InvestingPro Fair Value estimate of $248.09.
For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for ResMed, providing deeper insights into the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.